Skip to main content
S&P 5007,636.36-0.48%DOW52,380.66-0.77%NASDAQ26,253.34-0.64%BTC$78,136.00-0.80%ETH$2,465.32-1.24%GOLD$4,444.30-0.37%OIL$96.58+0.55%
Smart Investors Daily
VS

NASDAQ · VSTM

Verastem, Inc.

Healthcare · Biotechnology

$7.94

Down-$0.14 (-1.73%)

Updated Sep 10, 2026, 2:23 AM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
571.48M
P/E ratio
-3.75
Dividend yield
0.00%
52-week range
$3.43 – $8.54
Volume
2.4M
Avg. volume
2.24M

Price performance

VSTM price history

1M range · 20 trading sessions · Daily adjusted prices

VSTM closed at $7.94 after 20 trading sessions, up 14.24% for the selected period.

Last close
$7.94
Period change
+14.24%
Period low
$6.58
Period high
$8.20
Daily close
View OHLC price history
VSTM OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 9, 2026$8.01$8.38$7.80$7.942.4M
Sep 8, 2026$8.20$8.54$7.89$8.084.37M
Sep 4, 2026$7.91$8.21$7.72$8.202.3M
Sep 3, 2026$8.03$8.14$7.905$7.982.63M
Sep 2, 2026$7.70$8.095$7.68$8.025.26M
Sep 1, 2026$7.19$7.6399$7.13$7.612.08M
Aug 31, 2026$7.20$7.32$7.00$7.221.32M
Aug 28, 2026$7.32$7.38$7.18$7.221.08M
Aug 27, 2026$7.38$7.57$7.305$7.381.3M
Aug 26, 2026$7.08$7.45$6.91$7.391.68M
Aug 25, 2026$6.93$7.195$6.90$7.081.19M
Aug 24, 2026$6.90$6.955$6.62$6.861.17M
Aug 21, 2026$6.88$7.02$6.784$6.89996.12K
Aug 20, 2026$7.25$7.43$6.63$6.822.29M
Aug 19, 2026$7.65$7.86$7.20$7.2952.37M
Aug 18, 2026$7.18$7.678$7.18$7.432.92M
Aug 17, 2026$6.52$7.195$6.45$7.182.28M
Aug 14, 2026$6.66$6.66$6.44$6.581.28M
Aug 13, 2026$7.06$7.06$6.64$6.671.86M
Aug 12, 2026$7.01$7.1014$6.8905$6.951.26M

Latest VSTM news

The latest Smart Investors Daily articles mentioning VSTM.

Stock researchCompany · Overview

VSTM research

Overview

Company profile and research snapshot.

Company profile

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$14.00
Implied upside
—
Analysts
—
VSTM recent ratings
DateFirmRatingTarget
Aug 11, 2026MizuhoOutperform—
Aug 7, 2026GuggenheimBuy—
Jul 7, 2026RBC CapitalOutperform—
Jul 2, 2026BTIGBuy—
Jun 24, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers

BOSTON, September 08, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will host an investor event on Wednesday, October 14, at 8:00 am ET to present initial efficacy and updated safety and tolerability data for VS-7375 in pancreatic, lung, and colorectal cancers from the ongoing TARGET-D clinical development program. The upcoming presentation will build on the clinical u

Yahoo · Sep 2, 2026

Verastem Oncology to Participate in Upcoming September Investor Conferences

BOSTON, September 02, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate at the Wells Fargo 21st Annual Healthcare Conference on Sept. 8 in Boston and present at the following investor conferences:

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By